Published in J Clin Oncol on October 01, 2002
Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol (2011) 3.22
More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg (2006) 2.78
Limits of observational data in determining outcomes from cancer therapy. Cancer (2008) 1.97
African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomark (2007) 1.76
External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care (2006) 1.74
Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol (2014) 1.48
Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut (2007) 1.47
Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol (2014) 1.26
Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer (2012) 1.20
Validation of electronic data on chemotherapy and hormone therapy use in HMOs. Med Care (2013) 1.19
Race versus place of service in mortality among medicare beneficiaries with cancer. Cancer (2010) 1.13
ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract (2008) 1.10
Challenges in the management of stage II colon cancer. Semin Oncol (2011) 1.09
Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med (2013) 1.07
Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer. J Gerontol A Biol Sci Med Sci (2009) 1.07
Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer (2005) 1.07
Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst (2013) 1.02
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis (2007) 0.96
Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer (2011) 0.94
A black-white comparison of the quality of stage-specific colon cancer treatment. Cancer (2010) 0.93
Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancer. J Hematol Oncol (2011) 0.89
Patterns of Colorectal Cancer Care in the United States: 1990-2010. J Natl Cancer Inst (2015) 0.85
Screening mammography use and chemotherapy among female stage II colon cancer patients: a retrospective cohort study. BMC Health Serv Res (2010) 0.81
Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence. Surg Today (2013) 0.80
[Lymph node preparation in colorectal cancer. Ex vivo methylene blue injection as a novel technique to improve lymph node visualization]. Pathologe (2008) 0.80
Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution. Oncol Lett (2013) 0.80
Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol (2011) 0.80
Socioeconomic status and chemotherapy use for melanoma in older people. Can J Aging (2011) 0.80
Current status of gene expression profiling to assist decision making in stage II colon cancer. Oncologist (2014) 0.79
Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer. Int J Colorectal Dis (2011) 0.78
Chemotherapy for Stage II Colon Cancer. Clin Colon Rectal Surg (2015) 0.78
Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer (2016) 0.77
Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis. PLoS One (2013) 0.77
Assessing the quality of initial consultations regarding adjuvant colon cancer therapy. Clin Colorectal Cancer (2010) 0.77
Prognostic and Predictive Model for Stage II Colon Cancer Patients With Nonemergent Surgery: Who Should Receive Adjuvant Chemotherapy? Medicine (Baltimore) (2016) 0.77
Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer. BMC Cancer (2012) 0.76
High Expression of DARPP-32 in Colorectal Cancer Is Associated With Liver Metastases and Predicts Survival for Dukes A and B Patients: Results of a Pilot Study. Int Surg (2015) 0.76
The diffusion of docetaxel in patients with metastatic prostate cancer. J Natl Cancer Inst (2014) 0.75
Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer. J Surg Oncol (2013) 0.75
The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients. PLoS One (2014) 0.75
Exploring the medication duration based on the effect of traditional Chinese medicine on postoperative stage I-III colorectal patients: a retrospective cohort study. Oncotarget (2017) 0.75
Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) (2016) 0.75
Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer : a systematic review and meta-analysis. Oncotarget (2017) 0.75
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Computed tomography screening and lung cancer outcomes. JAMA (2007) 8.01
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Care patterns in Medicare and their implications for pay for performance. N Engl J Med (2007) 6.74
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol (2008) 5.78
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA (2004) 5.43
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 4.83
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Survival of blacks and whites after a cancer diagnosis. JAMA (2002) 4.27
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med (2003) 4.01
NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw (2008) 3.82
Two-stage designs for gene-disease association studies. Biometrics (2002) 3.67
Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med (2009) 3.59
Delivery of preventive services to older adults by primary care physicians. JAMA (2005) 3.53
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Maternal gestational diabetes, birth weight, and adolescent obesity. Pediatrics (2003) 3.27
Cost consequences of the 340B drug discount program. JAMA (2013) 3.17
Rapid-learning system for cancer care. J Clin Oncol (2010) 3.13
A paradigm shift in U.S. Breast reconstruction: increasing implant rates. Plast Reconstr Surg (2013) 3.00
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA (2003) 2.85
State expenditures for tobacco-control programs and the tobacco settlement. N Engl J Med (2002) 2.81
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol (2003) 2.69
How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood) (2010) 2.68
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol (2007) 2.53
Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum (2004) 2.52
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol (2005) 2.43
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol (2005) 2.38
Federal initiatives to support rapid learning about new technologies. Health Aff (Millwood) (2007) 2.36
Survivorship care plans in research and practice. CA Cancer J Clin (2012) 2.31
One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol (2011) 2.24
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol (2013) 2.20
Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. J Clin Oncol (2002) 2.20
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19
Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst (2005) 2.19
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 2.17
Two-stage designs for gene-disease association studies with sample size constraints. Biometrics (2004) 2.08
Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg (2012) 2.08
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
Reporting participation in case-control studies. Epidemiology (2002) 1.99
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol (2008) 1.97
The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg (2004) 1.97
Cancer's next frontier: addressing high and increasing costs. JAMA (2010) 1.93
Neuroendocrine tumors. J Natl Compr Canc Netw (2012) 1.91
Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg (2009) 1.88
The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer (2005) 1.86
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol (2010) 1.85
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev (2007) 1.76
Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol (2004) 1.74
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol (2003) 1.73
Lung cancer in US women: a contemporary epidemic. JAMA (2004) 1.70
Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology (2005) 1.69
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol (2005) 1.67
Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg (2002) 1.66
Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg (2005) 1.64
Attribution of deaths following cancer treatment. J Natl Cancer Inst (2002) 1.63
The epidemiology and costs of chronic critical illness. Crit Care Clin (2002) 1.63
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
Evaluating cancer epidemiologic risk factors using multiple primary malignancies. Epidemiology (2010) 1.58
Prevalence and risk factors for symptomatic thromboembolic events after shoulder arthroplasty. Clin Orthop Relat Res (2006) 1.55
Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst (2006) 1.55
Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol (2004) 1.54
Raising the bar for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 1.52
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.51
Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw (2015) 1.51
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Clinical prediction rule for atrial fibrillation after coronary artery bypass grafting. J Am Coll Cardiol (2004) 1.46
Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res (2009) 1.45
Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control (2007) 1.44
Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med (2007) 1.44
The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanoma. Stat Med (2008) 1.43
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat (2010) 1.40
Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer (2010) 1.40
Untreated patients in "CT screening for lung cancer: update 2007". Oncologist (2008) 1.38
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw (2009) 1.37
Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources. Med Care (2002) 1.36
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol (2013) 1.36
Translating genomics in cancer care. J Natl Compr Canc Netw (2013) 1.35
Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg (2004) 1.32
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res (2005) 1.31
Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst (2003) 1.31
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.31
Panitumumab. Nat Rev Drug Discov (2006) 1.31
Geographic access and the use of screening mammography. Med Care (2010) 1.30
Fragmentation of care for frequently hospitalized urban residents. Med Care (2006) 1.29
Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis (2012) 1.29